Media coverage – Artios Pharmaceuticals

Artios Pharmaceuticals steps up ovarian cancer fight

Ellie Wheeler — Fri, 09 Feb 2024 15:59:01 +0000

Artios Pharmaceuticals in Cambridge is steering a fresh initiative to fight ovarian cancer.

The company is pioneering the development of novel small molecule therapeutics that target the DNA damage response (DDR) process to treat patients with a broad range of cancers – but the new mission is special even by its own uncompromising standards.

Artios has triggered a randomised, Phase 2 expansion cohort in the ongoing Phase 1/2 trial evaluating its ataxia telangiectasia and Rad3-related (ATR) Inhibitor, ART0380, in combination with gemcitabine for the treatment of platinum resistant ovarian cancer.

Silverstein appointed Chief Financial Officer at Artios Pharmaceuticals

Ellie Wheeler — Fri, 09 Feb 2024 15:58:21 +0000

The best of Cambridge UK life science businesses are making encouraging headway commercially in the US and Artios Pharmaceuticals’s latest move looks set to provide another ‘wow’ moment on both sides of the Pond.

Artios has just hired biopharma industry class act Christine Silverstein as Chief Financial Officer. As CEO Niall Martin remarks, her track record of raising capital, preparing companies for IPO and experience with partnerships and M & A will position Artios for success as it continues to advance its leading DNA damage response (DDR) pipeline.

New Approaches for Cancer Therapies: Targeting the DNA Damage Response

Ellie Wheeler — Sat, 27 Jan 2024 15:46:56 +0000

The DNA damage response (DDR) is a mechanism within our cells that detects damaged DNA and supports its repair. Mutations in genes involved in this pathway are frequently found in cancers, which cause DNA to become increasingly unstable and promote tumor growth and development. As a result, targeting the DDR has become a promising prospect for the development of new cancer therapies.